A Phase 4, Observational Field Study to Evaluate the Safety and Clinical Benefit of TPOXX (Tecovirimat)-Treated Patients Following Exposure to Variola Virus and Clinical Diagnosis of Smallpox Disease
Latest Information Update: 06 Oct 2022
At a glance
- Drugs Tecovirimat (Primary)
- Indications Smallpox
- Focus Therapeutic Use
- Sponsors SIGA Technologies
Most Recent Events
- 28 Sep 2022 Status changed from recruiting to withdrawn prior to enrolment.
- 09 Jan 2020 Status changed from not yet recruiting to recruiting.
- 06 Jun 2019 New trial record